Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer

Table 5 The characteristics of patients with BRCA germline mutations

Serial Number	Age at diagnosis (yr)	BRCA mutation	Significance	Group assignment	PFS per study (mo)	PFS1	Recurrence
3	50	BRCA 1, Q1395X (4302C>T)	Deleterious	1	51.2+	73.2+	No
4	52	BRCA 1, 187del AG	Deleterious	1	15.5		Yes
7	58	BRCA 1, Q310X	Deleterious	1	14+	36+	No
22	56	BRCA 1, G1706E	Suspected deleterious	1	23.5		Yes, deceased
23	54	BRCA 1, unknown	Deleterious	1	12.9		Yes
28	41	BRCA 1, C64G (309T>G)	Deleterious	2	35.7+	53	Splenic recurrence, at 53 mo
35	40	BRCA 1, 187delAG	Deleterious	2	29.9+	51.9+	No

¹Progression free survival (PFS) used the cut of day of 1/30/2019. PFS per study used cut off day of March 30, 2017. PFS: Progression free survival.